Table 4.
Factors | Odds ratio of CR/PR (95% CI) |
P | HR of mortality (95% CI) |
P | HR of TRM (95% CI) |
P |
---|---|---|---|---|---|---|
Minnesota GVHD risk | ||||||
Standarda | 1.0 | 1.0 | 1.0 | |||
High | 0.4 (0.2–0.7) | <0.01 | 1.4 (0.9–2.2) | 0.11 | 1.7 (1.0–2.7) | 0.03 |
Donor type | <0.01 | <0.01 | <0.01 | |||
Matched/MM siblinga | 1.0 | 1.0 | 1.0 | |||
URD well matched | 1.5 (0.7–3.4) | 0.31 | 1.5 (0.8–2.6) | 0.22 | 1.8 (0.9–3.6) | 0.10 |
URD partial matched | 0.9 (0.4–1.9) | 0.78 | 1.9 (1.1–3.4) | 0.02 | 2.1 (1.1–4.0) | 0.03 |
URD mismatched | 0.4 (0.2–0.9) | 0.02 | 2.4 (1.4–4.0) | <0.01 | 2.9 (1.6–5.2) | <0.01 |
UCB | 1.7 (0.9–3.3) | 0.10 | 1.2 (0.7–2.0) | 0.41 | 1.0 (0.5–1.8) | 0.92 |
Reference group
Factors tested included all factors from univariate in a backward selection only keeping factors with overall p < 0.10 in final model. Organ involvement and grade of acute GVHD were not included due to collinearity with “new risk”. Lansky/Karnofsky was not included due to too many missing values. Age was treated as a continuous factor. Standard-risk disease includes acute leukemia/NHL in CR1 or CR2, CML in 1st chronic phase, MDS without excess blasts. High risk disease includes all others.
The Minnesota GVHD Risk Score was predictive of response regardless of transplant era